glp-1 gip medications muscle loss comparison agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Comparative efficacy and safety of

The intensive treatment of the multiple risk factors reduces the development/progression of renal disease18 which is why guidelines insist on comprehensive management of the patient with diabetes (glycemic control and control of cardiovascular risk factors, use of renin-angiotensin system inhibitors, as well as lifestyle changes, including smoking cessation or weight loss in overweight/obese individuals, among others).19 However, the residual renal risk remains very high in optimally treated patients.20 More recently, iSGLT2 has been shown to reduce the risk of cardiovascular and renal events, but still, the residual risk of renal disease progression remains high.21,22 Nevertheless, although the rate of diabetes-related complications (such as myocardial infarction, stroke, lower limb amputations or mortality) have decreased significantly in recent decades, this is not the same for CKD patients requiring renal replacement therapy attributed to diabetic kidney disease (DKD).23 Therefore new treatments are needed that improve glycemic control independently of GFR, with a low risk of hypoglycemia and able to reduce cardiovascular and renal risk in this population

Studi hanno indicato come lassunzione giornaliera dell'integratore fosse in grado di diminuire la sensazione di affaticamento di circa il 25%

The FDA approved this once-weekly injection on December 5, 2017, specifically for adults with type 2 diabetes to help regulate blood sugar levels when combined with diet and exercise

& Hayes, J

Contrary to the feedlot-finished animals, pasture-finished animals can more freely engage in natural behaviors, which could further positively impact their anti-oxidant status (Gatellier et al., 2004)